OncoImmunology | |
Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy | |
Anja Hoffmann1  Claudia Arndt1  Michael Bachmann1  Karla Elizabeth González Soto1  Nicola Mitwasi1  Anja Feldmann1  Liliana Rodrigues Loureiro1  Stefanie Koristka1  Alexandra Kegler1  Nicole Berndt1  Ralf Bergmann1  Chris Lamprecht1  Enrico Kittel-Boselli2  | |
[1] Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR);Tumor Immunology, University Cancer Center (UCC), University Hospital Carl Gustav Carus Dresden; | |
关键词: chimeric antigen receptor (car); t cell therapy; tumor immunotherapy; adaptor car platform; combinatorial gated targeting; | |
DOI : 10.1080/2162402X.2020.1785608 | |
来源: DOAJ |
【 摘 要 】
Chimeric antigen receptor (CAR) T cells show remarkable therapeutic effects in some hematological malignancies. However, CAR T cells can also cause life-threatening side effects. In order to minimize off-target and on-target/off-tumor reactions, improve safety, enable controllability, provide high flexibility, and increase tumor specificity, we established a novel humanized artificial receptor platform termed RevCARs. RevCAR genes encode for small surface receptors lacking any antigen-binding moiety. Steering of RevCAR T cells occurs via bispecific targeting molecules (TMs). The small size of RevCAR-encoding genes allows the construction of polycistronic vectors. Here, we demonstrate that RevCAR T cells efficiently kill tumor cells, can be steered by TMs, flexibly redirected against multiple targets, and used for combinatorial targeting following the “OR” and “AND” gate logic.
【 授权许可】
Unknown